导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -10.59% | 3791/4773 |
| 近一周 | -1.93% | 905/5462 |
| 近一月 | -0.59% | 797/5421 |
| 近一季 | 3.84% | 342/5209 |
| 近半年 | -8.69% | 3382/4920 |
| 近一年 | -14.52% | 3648/4366 |
| 近两年 | 8.46% | 2817/2954 |
| 近三年 | -9.58% | 2024/2253 |
| 成立以来 | 13.96% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.11% 3766/4961 |
-13.26% 4481/5312 |
- - |
- - |
| 2025 | 0.21% 3278/4813 |
-0.32% 2199/3635 |
-2.97% 3398/4076 |
5.96% 3559/4524 |
-2.23% 3107/4813 |
| 2024 | 7.95% 1601/3463 |
4.93% 414/2808 |
-5.29% 1685/3014 |
14.89% 1885/3129 |
-5.46% 2562/3463 |
| 2023 | -15.26% 1642/2656 |
1.86% 1495/2280 |
-9.81% 2072/2385 |
-2.27% 654/2515 |
-5.61% 1419/2655 |
| 2022 | -15.68% 426/2207 |
-18.73% 1385/1919 |
16.41% 151/2016 |
-11.71% 564/2113 |
0.95% 1423/2208 |
| 2021 | -6.10% 997/1822 |
-3.93% 835/1255 |
5.45% 808/1330 |
-10.60% 1229/1466 |
3.68% 402/1822 |
| 2020 | - - |
- - |
- - |
16.67% 140/1164 |
21.47% 53/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 东兴中证消费50A VS. 长安沪深300非周期A(740101) |